Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:10/9/2009

relating to the offering was filed with the SEC on October 6, 2009. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at www.sec.gov.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX fails to submit an ANX-530 NDA, whether by December 31, 2009 or at all; the risk the FDA will determine that ANX-530 and Navelbine® are not bioequivalent or for the FDA to require additional preclinical work and/or clinical activities to support the submiss
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
2. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
3. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
4. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
9. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
10. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015   Millar, Inc. , a ... announced the 2016 retirement of Craig Thummel , ... 12 years of service to the Company. The Company ... senior members of the Executive Management team as his ... Daugherty , currently Director of Sales and Marketing, as ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 /PRNewswire/ ... a late stage pharmaceutical company focused on the ... today announced the closing of its previously announced ... stock. The underwriters also exercised their over-allotment option ... of common stock. The net proceeds ...
(Date:6/30/2015)... June 24, 2015 ... addition of the "Global Array Instruments Market ... The global array instruments market to grow at ... 2014-2019 The global array instruments market can ... microarrays, and others including tissue microarrays and cell ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Roche announced today the opening of a new ... Nutley, N.J. The Roche Center of Excellence produces dosage ... and Phase 1 and 2 clinical studies. The 17,000 ... compounds into medicines for clinical trials. ...
... Sept. 30, 2011 The CyberKnife Coalition ... the CyberKnife Robotic Radiosurgery System® have now been enrolled ... track prostate cancer patients treated with stereotactic ... Radiosurgery (RPCR), tracks clinical and functional outcomes of men ...
Cached Medicine Technology:Roche Opens New Center of Excellence Facility 2First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2
(Date:6/30/2015)... ... 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of premium ... new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus on ... have come to know and respect for over eight years. , “I am thrilled ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... the community. , Eleven physicians from Allied’s Fullerton division volunteered to help provide ... annual Super Surgery Saturday, March 21, at St. Jude Medical Center. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice ... family of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Red Hot ... in a recent online poll at http://scoutology.com/novaburgerwars and was selected as “Best ... published in August 2015. , Red Hot & Blue President Randy McCann said, “Everyone ...
(Date:6/30/2015)... ... June 30, 2015 , ... An opinion ... that fat transfer procedures had over breast implants when reconstructing breasts after a ... that “look and feel natural,” have increased sensation, and are less likely than ...
Breaking Medicine News(10 mins):Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3
... Wake Forest University Baptist Medical Center, US, have found ... children with cancer, and thus limits the side effects ... looked into the chemotherapy given to children suffering from ... type of childhood cancer were administered very limited dosage ...
... may be used to treat the problem of severe ... palsy. ,Children suffering from cerebral palsy and other ... have the control over the salivary reflex. This condition ... from being a constant problem for parents or people ...
... Medical School say that for people whose blood pressure do ... levels. ,In a healthy normal person blood pressure ... late night, or sleep disturbances may elevate the nighttime blood ... fact such higher levels of blood pressure at night may ...
... Researchers have identified a virus that targets and kills a ... virus (VSV) can successfully target and kill glioblastoma, which is ... a form of brain tumor that is resistant to modern ... Medicine had taken nine different DNA and RNA viruses through ...
... had invented a therapeutic vaccine Cytos002-NicQb that can cure//smokers ... quit smoking. ,Swiss researchers for the study, in ... had said that the vaccine for nicotine dependence had ... trials successfully. The first phase of the study had ...
... by Harvard School of Public Health suggests that obesity ... if already existing. ,Obesity had been conclusively associated ... and certain forms of cancer. This is for the ... asthma. ,In obese people lungs are under-expanded and ...
Cached Medicine News:
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: